Evidence map›Paper›PMID 29686383›Full record

Trial reportNature communications2018

The IL-33-PIN1-IRAK-M axis is critical for type 2 immunity in IL-33-induced allergic airway inflammation.

Morris Nechama, Jeahoo Kwon, Shuo Wei, Adrian Tun Kyi, Robert S Welner, Iddo Z Ben-Dov, Mohamed S Arredouani, John M Asara, Chun-Hau Chen, Cheng-Yu Tsai and 6 more

Erratum issuedOpen access · goldAbstract readClinical Trial
In one paragraph

Trial report in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 52 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 2 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 2 syntheses or guidelines pooled it, 94 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Targeting alarmins in asthma: From bench to clinic.The Journal of allergy and clinical immunology · 2025
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Pin1 and Alzheimer's disease.Translational research : the journal of laboratory and clinical medicine · 2023
    Review
  17. Article
  18. Review
  19. Article
  20. The IRAK-M death domain: a tale of three surfaces.Frontiers in molecular biosciences · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 3 countries.

Morris NechamaDivision of Translational Therapeutics, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
Jeahoo KwonDepartment of Molecular Biology & Genetics, Cornell University, Ithaca, NY, 14853, USA.
Shuo WeiDivision of Translational Therapeutics, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
Adrian Tun KyiDivision of Translational Therapeutics, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
Robert S WelnerDivision of Translational Therapeutics, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
Iddo Z Ben-DovDepartment of Nephrology and Hypertension, Hadassah-Hebrew Medical Center, 91120, Jerusalem, Israel.ORCID http://orcid.org/0000-0002-9180-3604
Mohamed S ArredouaniDivision of Translational Therapeutics, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
John M AsaraDivision of Translational Therapeutics, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
Chun-Hau ChenDivision of Translational Therapeutics, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
Cheng-Yu TsaiDivision of Translational Therapeutics, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
Kyle F NelsonDepartment of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.
Koichi S KobayashiDepartment of Microbial Pathogenesis & Immunology, Texas A&M Health Science Center, College Station, TX, 77843, USA.
Elliot IsraelDepartment of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.
Xiao Zhen ZhouDivision of Translational Therapeutics, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
Linda K NicholsonDepartment of Molecular Biology & Genetics, Cornell University, Ithaca, NY, 14853, USA. lkn2@cornell.edu.
Kun Ping LuDivision of Translational Therapeutics, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA. klu@bidmc.harvard.edu.
Beth Israel Deaconess Medical Center · USBrigham and Women's Hospital · USCornell University · USBroad Institute · USHadassah Medical Center · ILTexas A&M Health Science Center · US

Funding

Development of selective Pin1 inhibitors to target a common oncogenic mechanismR01CA205153 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI GRAY, NATHANAEL SCHIANDER, WULF, GERBURG M · 2017 to 2021
$3.3M
Role of the Prolyl Isomerase Pin1 in the Development and Treatment of AsthmaR01HL111430 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI LU, KUN PING · 2012 to 2015
$2.7M
Function and Regulation of the Phosphorylation-Specific Prolyl Isomerase Pin1R01CA167677 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI LU, KUN PING · 2012 to 2016
$1.9M
NCI NIH HHS R01 CA167677NCI NIH HHS R01 CA205153NHLBI NIH HHS R01 HL111430NIH HHS R01CA167677NIH HHS R01HL111430
6 · The paper itself

Abstract

Interleukin 33 (IL-33) is among the earliest-released cytokines in response to allergens that orchestrate type 2 immunity. The prolyl cis-trans isomerase PIN1 is known to induce cytokines for eosinophil survival and activation by stabilizing cytokines mRNAs, but the function of PIN1 in upstream signaling pathways in asthma is unknown. Here we show that interleukin receptor associated kinase M (IRAK-M) is a PIN1 target critical for IL-33 signaling in allergic asthma. NMR analysis and docking simulations suggest that PIN1 might regulate IRAK-M conformation and function in IL-33 signaling. Upon IL-33-induced airway inflammation, PIN1 is activated for binding with and isomerization of IRAK-M, resulting in IRAK-M nuclear translocation and induction of selected proinflammatory genes in dendritic cells. Thus, the IL-33-PIN1-IRAK-M is an axis critical for dendritic cell activation, type 2 immunity and IL-33 induced airway inflammation.

Indexed as

Immunity, CellularAdultAnimalsAntigens, DermatophagoidesAsthmaBronchial Provocation TestsBronchoalveolar Lavage FluidCell LineDisease Models, AnimalEosinophilsFemaleHEK293 CellsHumansInterleukin-1 Receptor-Associated KinasesInterleukin-33LungAntigens, DermatophagoidesInterleukin-1 Receptor-Associated KinasesInterleukin-33IRAK3 protein, humanIrak3 protein, mouseNIMA-Interacting Peptidylprolyl IsomerasePIN1 protein, humanPin1 protein, mouse

Identifiers

PMID29686383
PMCPMC5913134
OpenAlexW2802626256

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.